Fig. 4

MCF-7 Cell viability of the synergy group compared with the chemotherapy groups (A) and hyperthermia groups (B). (**p < 0.01, ***p < 0.001).SK-BR-3 Cell viability of the synergy group compared with the chemotherapy groups (C) and hyperthermia groups (D). (*p < 0.05, **p < 0.01, ***p < 0.001) (E) MCF-7 cell uptake of TSL-C6 and TSL-C6-HER2 and SK-BR-3 cell uptake of TSL-C6 and TSL-C6-HER2 (Scale bar = 50 μm). Mean fluorescence intensity of TSL-C6 and TSL-C6-HER2 in SK-BR-3 cells (F) and MCF-7 cells (G) (*p < 0.05, **p < 0.01, ***p < 0.001). H Quantitative comparation of GTS-CYC-HER2@NIR uptaken into SK-BR-3 cells with or without HER2 antibody blocking (***P < 0.001)